The U.S. Food and Drug Administration (FDA) has granted fast track designation to muzastotug when used in combination with Keytruda (pembrolizumab) to treat adult patients with microsatellite stable ...
Treatment with bleximenib and Venclexta (venetoclax) showed a tolerable safety profile in a phase 1b trial for patients with ...
Bleximenib and Venclexta treatment were well tolerated in a phase 1b trial for relapsed/refractory acute myeloid leukemia with mostly low-grade side effects.
Time and resilience have transformed the author's cancer experience into a fading memory, allowing life to return to normal.
The U.S. Food and Drug Administration (FDA) has approved Enhertu (fam-trastuzumab deruxtecan-nxki) in combination with ...
Stage 4 metastatic breast cancer presents significant emotional and psychological challenges, requiring patients to adapt ...
The FDA has granted breakthrough therapy designation to INCA033989 for some patients with essential thrombocythemia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback